Compare Adaptive Biotechnologies Corp (ADPT) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Johnson Controls International PLC — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Johnson Controls International PLC trades at $139.52 (market cap $85.79B). The key difference: Johnson Controls International PLC is far larger — about 25.8× Adaptive Biotechnologies Corp's market cap, and Johnson Controls International PLC pays a 1.14% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JCI | |
|---|---|---|
Market Cap | $3.33B | $85.79B |
Sector | Health | Industrials |
52-Week High | $22.37 | $148.21 |
52-Week Low | $10.24 | $103.24 |
Enterprise Value | $3.19B | $94.62B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Johnson Controls International (JCI) trades at $140.62, down 0.1% on the day, with strong analyst support showing 62% buy ratings and a consensus price target of $153.67. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.19 surpassing the $1.12 estimate. The company maintains solid profitability with a 14.45% net income margin and recently announced a $0.40 dividend payable in July 2026. Technical indicators show a bullish trend with support at $139 and resistance at $145.
JCI presents a favorable investment case with earnings momentum, strong analyst conviction, and exposure to growing markets like data center cooling. Key risks include elevated valuation multiples (P/E of 43.65) and increasing debt-to-asset ratios. The stock's current price offers approximately 9% upside to consensus targets, though investors should monitor execution on revenue growth projections and competitive pressures in the building solutions sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
